Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
COSM vs HROW vs NTRB vs XTLB vs CODA
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Biotechnology
Biotechnology
Aerospace & Defense
COSM vs HROW vs NTRB vs XTLB vs CODA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Biotechnology | Biotechnology | Aerospace & Defense |
| Market Cap | $11M | $1.45B | $46M | $294K | $134M |
| Revenue (TTM) | $60M | $272M | $2M | $451K | $28M |
| Net Income (TTM) | $-19M | $-5M | $-8M | $-1M | $4M |
| Gross Margin | 11.4% | 75.1% | 24.9% | 26.4% | 66.3% |
| Operating Margin | -23.9% | 11.2% | -408.4% | -481.6% | 17.4% |
| Forward P/E | — | 82.9x | — | — | 22.5x |
| Total Debt | $12M | $252M | $210K | $138K | $395K |
| Cash & Equiv. | $315K | $73M | $5M | $371K | $29M |
COSM vs HROW vs NTRB vs XTLB vs CODA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Oct 21 | May 26 | Return |
|---|---|---|---|
| Cosmos Health Inc. (COSM) | 100 | 8.5 | -91.5% |
| Harrow Health, Inc. (HROW) | 100 | 387.0 | +287.0% |
| Nutriband Inc. (NTRB) | 100 | 70.6 | -29.4% |
| XTL Biopharmaceutic… (XTLB) | 100 | 17.5 | -82.5% |
| Coda Octopus Group,… (CODA) | 100 | 141.0 | +41.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: COSM vs HROW vs NTRB vs XTLB vs CODA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
COSM is the #2 pick in this set and the best alternative if dividends is your priority.
- 92.4% yield; 1-year raise streak; the other 4 pay no meaningful dividend
HROW ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 36.4%, EPS growth 71.4%, 3Y rev CAGR 45.4%
- 9.1% 10Y total return vs CODA's 8.4%
- 36.4% revenue growth vs XTLB's -173.2%
NTRB is the clearest fit if your priority is income & stability.
- Dividend streak 1 yrs, beta 1.20
Among these 5 stocks, XTLB doesn't own a clear edge in any measured category.
CODA carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 1.00, Low D/E 0.7%, current ratio 8.86x
- Beta 1.00, current ratio 8.86x
- Better valuation composite
- 14.8% margin vs NTRB's -404.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 36.4% revenue growth vs XTLB's -173.2% | |
| Value | Better valuation composite | |
| Quality / Margins | 14.8% margin vs NTRB's -404.1% | |
| Stability / Safety | Beta 1.00 vs HROW's 2.13, lower leverage | |
| Dividends | 92.4% yield; 1-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +78.9% vs XTLB's -50.9% | |
| Efficiency (ROA) | 6.6% ROA vs NTRB's -101.9%, ROIC 11.2% vs -270.2% |
COSM vs HROW vs NTRB vs XTLB vs CODA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
COSM vs HROW vs NTRB vs XTLB vs CODA — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CODA leads in 1 of 6 categories
HROW leads 1 • COSM leads 0 • NTRB leads 0 • XTLB leads 0 • 4 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — HROW and CODA each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HROW is the larger business by revenue, generating $272M annually — 603.8x XTLB's $451,000. CODA is the more profitable business, keeping 14.8% of every revenue dollar as net income compared to NTRB's -4.0%. On growth, COSM holds the edge at +37.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $60M | $272M | $2M | $451,000 | $28M |
| EBITDAEarnings before interest/tax | -$13M | $59M | -$8M | -$1M | $6M |
| Net IncomeAfter-tax profit | -$19M | -$5M | -$8M | -$1M | $4M |
| Free Cash FlowCash after capex | -$10M | $73M | -$5M | $0 | $7M |
| Gross MarginGross profit ÷ Revenue | +11.4% | +75.1% | +24.9% | +26.4% | +66.3% |
| Operating MarginEBIT ÷ Revenue | -23.9% | +11.2% | -4.1% | -4.8% | +17.4% |
| Net MarginNet income ÷ Revenue | -31.0% | -1.9% | -4.0% | -2.3% | +14.8% |
| FCF MarginFCF ÷ Revenue | -17.2% | +26.8% | -2.5% | -3.7% | +24.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +37.9% | +33.3% | -37.6% | — | +28.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +62.2% | -5.3% | +84.4% | +20.0% | +3.0% |
Valuation Metrics
Evenly matched — COSM and HROW and XTLB and CODA each lead in 1 of 4 comparable metrics.
Valuation Metrics
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $11M | $1.5B | $46M | $293,767 | $134M |
| Enterprise ValueMkt cap + debt − cash | $23M | $1.6B | $42M | $60,767 | $106M |
| Trailing P/EPrice ÷ TTM EPS | -0.30x | -278.93x | -1.47x | -0.28x | 32.16x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 82.86x | — | — | 22.45x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 7.51x |
| EV / EBITDAEnterprise value multiple | — | — | — | — | 17.85x |
| Price / SalesMarket cap ÷ Revenue | 0.20x | 5.34x | 22.66x | 0.65x | 5.05x |
| Price / BookPrice ÷ Book value/share | 0.27x | 27.56x | 6.61x | 0.05x | 2.30x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 22.20x |
Profitability & Efficiency
CODA leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
CODA delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-118 for NTRB. CODA carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to HROW's 4.84x. On the Piotroski fundamental quality scale (0–9), CODA scores 7/9 vs XTLB's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -80.1% | -10.1% | -118.3% | -25.5% | +7.2% |
| ROA (TTM)Return on assets | -26.7% | -1.4% | -101.9% | -17.7% | +6.6% |
| ROICReturn on invested capital | -28.9% | +9.5% | -2.7% | -54.1% | +11.2% |
| ROCEReturn on capital employed | -44.3% | +10.2% | -125.5% | -50.7% | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 3 | 3 | 7 |
| Debt / EquityFinancial leverage | 0.48x | 4.84x | 0.03x | 0.03x | 0.01x |
| Net DebtTotal debt minus cash | $12M | $179M | -$4M | -$233,000 | -$28M |
| Cash & Equiv.Liquid assets | $315,105 | $73M | $5M | $371,000 | $29M |
| Total DebtShort + long-term debt | $12M | $252M | $209,629 | $138,000 | $394,932 |
| Interest CoverageEBIT ÷ Interest expense | -9.42x | 0.53x | -369.11x | -13.31x | — |
Total Returns (Dividends Reinvested)
HROW leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HROW five years ago would be worth $47,797 today (with dividends reinvested), compared to $547 for COSM. Over the past 12 months, CODA leads with a +78.9% total return vs XTLB's -50.9%. The 3-year compound annual growth rate (CAGR) favors HROW at 12.7% vs COSM's -52.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -32.0% | -21.8% | -14.4% | +11.3% | +25.1% |
| 1-Year ReturnPast 12 months | -17.0% | +58.8% | -34.4% | -50.9% | +78.9% |
| 3-Year ReturnCumulative with dividends | -89.5% | +43.0% | +10.8% | -45.7% | +34.5% |
| 5-Year ReturnCumulative with dividends | -94.5% | +378.0% | -34.0% | -80.4% | +49.7% |
| 10-Year ReturnCumulative with dividends | +37.8% | +914.3% | -34.0% | -87.3% | +844.4% |
| CAGR (3Y)Annualised 3-year return | -52.8% | +12.7% | +3.5% | -18.4% | +10.4% |
Risk & Volatility
Evenly matched — HROW and CODA each lead in 1 of 2 comparable metrics.
Risk & Volatility
CODA is the less volatile stock with a 1.00 beta — it tends to amplify market swings less than HROW's 2.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HROW currently trades 71.2% from its 52-week high vs XTLB's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.72x | 2.13x | 1.20x | 1.71x | 1.00x |
| 52-Week HighHighest price in past year | $1.32 | $54.85 | $11.68 | $10.28 | $17.28 |
| 52-Week LowLowest price in past year | $0.28 | $21.12 | $3.42 | $1.05 | $5.98 |
| % of 52W HighCurrent price vs 52-week peak | +26.5% | +71.2% | +32.4% | +26.0% | +68.9% |
| RSI (14)Momentum oscillator 0–100 | 48.6 | 54.6 | 50.8 | 57.0 | 48.6 |
| Avg Volume (50D)Average daily shares traded | 793K | 733K | 11K | 2.4M | 256K |
Analyst Outlook
Evenly matched — COSM and NTRB each lead in 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: HROW as "Buy", CODA as "Buy". Consensus price targets imply 93.8% upside for HROW (target: $76) vs 17.6% for CODA (target: $14). COSM is the only dividend payer here at 92.44% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | — | — | Buy |
| Price TargetConsensus 12-month target | — | $75.67 | — | — | $14.00 |
| # AnalystsCovering analysts | — | 10 | — | — | 1 |
| Dividend YieldAnnual dividend ÷ price | +92.4% | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 | 1 | — | 0 |
| Dividend / ShareAnnual DPS | $0.32 | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
CODA leads in 1 of 6 categories (Profitability & Efficiency). HROW leads in 1 (Total Returns). 4 tied.
COSM vs HROW vs NTRB vs XTLB vs CODA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is COSM or HROW or NTRB or XTLB or CODA a better buy right now?
For growth investors, Harrow Health, Inc.
(HROW) is the stronger pick with 36. 4% revenue growth year-over-year, versus -4. 8% for Nutriband Inc. (NTRB). Coda Octopus Group, Inc. (CODA) offers the better valuation at 32. 2x trailing P/E (22. 5x forward), making it the more compelling value choice. Analysts rate Harrow Health, Inc. (HROW) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — COSM or HROW or NTRB or XTLB or CODA?
On forward P/E, Coda Octopus Group, Inc.
is actually cheaper at 22. 5x.
03Which is the better long-term investment — COSM or HROW or NTRB or XTLB or CODA?
Over the past 5 years, Harrow Health, Inc.
(HROW) delivered a total return of +378. 0%, compared to -94. 5% for Cosmos Health Inc. (COSM). Over 10 years, the gap is even starker: HROW returned +914. 3% versus XTLB's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — COSM or HROW or NTRB or XTLB or CODA?
By beta (market sensitivity over 5 years), Coda Octopus Group, Inc.
(CODA) is the lower-risk stock at 1. 00β versus Harrow Health, Inc. 's 2. 13β — meaning HROW is approximately 112% more volatile than CODA relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — COSM or HROW or NTRB or XTLB or CODA?
By revenue growth (latest reported year), Harrow Health, Inc.
(HROW) is pulling ahead at 36. 4% versus -4. 8% for Nutriband Inc. (NTRB). On earnings-per-share growth, the picture is similar: Harrow Health, Inc. grew EPS 71. 4% year-over-year, compared to -160. 6% for Nutriband Inc.. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — COSM or HROW or NTRB or XTLB or CODA?
Coda Octopus Group, Inc.
(CODA) is the more profitable company, earning 15. 5% net margin versus -404. 1% for Nutriband Inc. — meaning it keeps 15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CODA leads at 17. 1% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — HROW leads at 75. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is COSM or HROW or NTRB or XTLB or CODA more undervalued right now?
On forward earnings alone, Coda Octopus Group, Inc.
(CODA) trades at 22. 5x forward P/E versus 82. 9x for Harrow Health, Inc. — 60. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HROW: 93. 8% to $75. 67.
08Which pays a better dividend — COSM or HROW or NTRB or XTLB or CODA?
In this comparison, COSM (92.
4% yield) pays a dividend. HROW, NTRB, XTLB, CODA do not pay a meaningful dividend and should not be held primarily for income.
09Is COSM or HROW or NTRB or XTLB or CODA better for a retirement portfolio?
For long-horizon retirement investors, Coda Octopus Group, Inc.
(CODA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00), +844. 4% 10Y return). XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CODA: +844. 4%, XTLB: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between COSM and HROW and NTRB and XTLB and CODA?
These companies operate in different sectors (COSM (Healthcare) and HROW (Healthcare) and NTRB (Healthcare) and XTLB (Healthcare) and CODA (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: COSM is a small-cap income-oriented stock; HROW is a small-cap high-growth stock; NTRB is a small-cap quality compounder stock; XTLB is a small-cap quality compounder stock; CODA is a small-cap high-growth stock. COSM pays a dividend while HROW, NTRB, XTLB, CODA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.